Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System

Ligelizumab is a highly potent, humanized IgG1, anti-IgE monoclonal antibody. To explore its optimal subcutaneous delivery, the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of ligelizumab from two Phase 1 studies in healthy volunteers (HVs) and four Phase 2 and 3 studies in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Yan, Calonder, Claudio, Kirsilä, Tiina, Burciu, Alis, Tisu, Matjaz, Joubert, Yolandi, Laurent, Nathalie, Hua, Eva, Patekar, Manmath, Drollmann, Anton, Woessner, Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535857/
https://www.ncbi.nlm.nih.gov/pubmed/37765235
http://dx.doi.org/10.3390/pharmaceutics15092266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535857/
https://www.ncbi.nlm.nih.gov/pubmed/37765235
http://dx.doi.org/10.3390/pharmaceutics15092266

Ejemplares similares